A review article published in BiomolBiomed by authors from University of Zagreb, Croatia and Qatar University, Qatar, has shed light on the role of the enzyme glycogen synthase kinase (GSK) in ovarian cancer development. The article shows that GSK plays a critical role in carcinogenesis and that its activity is associated with advanced FIGO stages and elevated CA -125 levels in some tumors.
The article found that in some tumours, GSK promotes tumour development, while in others, it acts as a tumour suppressor. Moreover, treatment with a GSK3 inhibitor can reduce the growth of malignant cells, suggesting that GSK3 is a driving force in ovarian cancer development.
The article also highlights that various Akt activators decrease GSK3 activity, which promotes ovarian cancer development. In contrast, Akt inhibitors restitute GSK3 activity, which results in cancer growth arrest. These findings show that the exact role of GSK3 in ovarian cancer development is not clear yet, and there are two opposite therapeutic approaches targeting GSK3: activation and inhibition.
Many drugs are currently undergoing evaluation and clinical trials. Therefore, this article calls for further research to better understand the exact role of GSK3 in ovarian cancer development and develop targeted therapies for ovarian cancer patients.
For more information on this topic, please read the full article here.
Reference: Glibo M, Serman A, Karin-Kujundzic V, Bekavac Vlatkovic I, Miskovic B, Vranic S, Serman L. The role of glycogen synthase kinase 3 (GSK3) in cancer with emphasis on ovarian cancer development and progression: A comprehensive review. Biomol Biomed [Internet]. 2021Feb.1 [cited 2023Apr.29];21(1):5-18. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/5036
Leave a Reply